LEngLEng的个人主页 - 老虎社区

LEngLEng

LEngLEng

暂无个人介绍

IP属地：未知

23关注

7粉丝

0主题

0勋章

2021-12-20

$IFAST CORPORATION LTD.(AIY.SI)$$7.50? 🤔

2021-12-16

$Pfizer(PFE)$👏🏻 Keep gg up!

2021-11-29

Great!

Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week

2021-11-12

$AEM HOLDINGS LTD(AWX.SI)$Wow…👍🏼 Any good news for today bull run?

2021-11-03

Good!

UOB Q3 profit rises 57% to $1.05 billion, topping estimates

2021-11-01

$AEM HOLDINGS LTD(AWX.SI)$Mthly post. Waiting it to take off 🚀 to the next level😎

2021-10-03

Good news 👍🏼

Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News

2021-10-03

In watchlist

抱歉，原内容已删除

2021-10-01

$SHENG SIONG GROUP LTD(OV8.SI)$Be clam

2021-09-30

$AEM HOLDINGS LTD(AWX.SI)$Mthly post.time to accumulate?

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3569379973417395,"uuid":"3569379973417395","gmtCreate":1606289427685,"gmtModify":1634522684291,"name":"LEngLEng","pinyin":"lengleng","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":23,"tweetSize":23,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.29","exceedPercentage":"80.90%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.03%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":693319960,"gmtCreate":1639969831044,"gmtModify":1639969831174,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AIY.SI\">$IFAST CORPORATION LTD.(AIY.SI)$</a>$7.50? 🤔","listText":"<a href=\"https://laohu8.com/S/AIY.SI\">$IFAST CORPORATION LTD.(AIY.SI)$</a>$7.50? 🤔","text":"$IFAST CORPORATION LTD.(AIY.SI)$$7.50? 🤔","images":[{"img":"https://static.tigerbbs.com/54e5e42853b745936f11f12a89fba6b7","width":"750","height":"1687"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693319960","isVote":1,"tweetType":1,"viewCount":955,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":690236166,"gmtCreate":1639668541645,"gmtModify":1639668564381,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>👏🏻 Keep gg up!","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>👏🏻 Keep gg up!","text":"$Pfizer(PFE)$👏🏻 Keep gg up!","images":[{"img":"https://static.tigerbbs.com/93f1b8a0fa8decc2bbbbcfdff64c20fc","width":"750","height":"2214"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/690236166","isVote":1,"tweetType":1,"viewCount":368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":600222582,"gmtCreate":1638161340954,"gmtModify":1638161341059,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600222582","repostId":"1119853738","repostType":2,"repost":{"id":"1119853738","pubTimestamp":1638153494,"share":"https://www.laohu8.com/m/news/1119853738?lang=&edition=full","pubTime":"2021-11-29 10:38","market":"us","language":"en","title":"Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1119853738","media":"Motley Fool","summary":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday","content":"<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.</p>\n<p>While there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.</p>\n<p>How should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers&nbsp;<b>Moderna</b>(NASDAQ:MRNA),<b>Pfizer</b>(NYSE:PFE), and&nbsp;<b>Novavax</b>(NASDAQ:NVAX)&nbsp;all&nbsp;vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.</p>\n<p>The pandemic's latest twist makes these three stocks screaming buys</p>\n<p>Moderna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.</p>\n<p>Pfizer, for its part, said that its&nbsp;<b>BioNTech</b>-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.</p>\n<p>Why are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.</p>\n<p>While Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.</p>\n<p>On the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have&nbsp;dipped in the back half of 2021&nbsp;in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.</p>\n<p>What's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.</p>\n<p>In short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Pfizer, and Novavax Are Must-Own Stocks This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119853738","content_text":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.\nWhile there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.\nHow should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers Moderna(NASDAQ:MRNA),Pfizer(NYSE:PFE), and Novavax(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.\nThe pandemic's latest twist makes these three stocks screaming buys\nModerna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.\nPfizer, for its part, said that its BioNTech-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.\nWhy are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.\nWhile Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.\nOn the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.\nWhat's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.\nIn short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879160532,"gmtCreate":1636691198526,"gmtModify":1636691198821,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Wow…👍🏼&nbsp;Any good news for today bull run?","listText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Wow…👍🏼&nbsp;Any good news for today bull run?","text":"$AEM HOLDINGS LTD(AWX.SI)$Wow…👍🏼 Any good news for today bull run?","images":[{"img":"https://static.tigerbbs.com/40bd68542e08820e79726dd8a908399e","width":"750","height":"1460"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879160532","isVote":1,"tweetType":1,"viewCount":555,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841868505,"gmtCreate":1635901814533,"gmtModify":1635901814635,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841868505","repostId":"2180317907","repostType":4,"repost":{"id":"2180317907","pubTimestamp":1635898938,"share":"https://www.laohu8.com/m/news/2180317907?lang=&edition=full","pubTime":"2021-11-03 08:22","market":"sg","language":"en","title":"UOB Q3 profit rises 57% to $1.05 billion, topping estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2180317907","media":"The Straits Times","summary":"SINGAPORE - UOB's earnings continued to rebound from last year on the back of loan growth and sustai","content":"<div>\n<p>SINGAPORE - UOB's earnings continued to rebound from last year on the back of loan growth and sustained fee income, as well as lower allowances.\nSingapore's third-largest lender on Wednesday (Nov 3) ...</p>\n\n<a href=\"http://www.straitstimes.com/business/banking/uob-q3-profit-rises-57-to-105-billion-topping-estimates\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UOB Q3 profit rises 57% to $1.05 billion, topping estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUOB Q3 profit rises 57% to $1.05 billion, topping estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 08:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/business/banking/uob-q3-profit-rises-57-to-105-billion-topping-estimates><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE - UOB's earnings continued to rebound from last year on the back of loan growth and sustained fee income, as well as lower allowances.\nSingapore's third-largest lender on Wednesday (Nov 3) ...</p>\n\n<a href=\"http://www.straitstimes.com/business/banking/uob-q3-profit-rises-57-to-105-billion-topping-estimates\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U11.SI":"大华银行"},"source_url":"http://www.straitstimes.com/business/banking/uob-q3-profit-rises-57-to-105-billion-topping-estimates","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180317907","content_text":"SINGAPORE - UOB's earnings continued to rebound from last year on the back of loan growth and sustained fee income, as well as lower allowances.\nSingapore's third-largest lender on Wednesday (Nov 3) posted a 57 per cent year-on-year increase in third-quarter net profit to $1.05 billion - slightly above the $1 billion average estimate of four analysts polled by Bloomberg.\nUOB chief Wee Ee Cheong said the bank's results came amid a challenging macroeconomic backdrop with disruptions in global supply chains, a slowdown in China's economy and resurgent Covid-19 infections across the region.\n\"Amid near-term uncertainties, the gradual reopening of borders bodes well for business flows and we remain positive of strong activities along the Greater China-Asean trade corridors,\" he added.\nNet interest income climbed 9 per cent to $1.6 billion while net interest margin - a key gauge of banks' profitability - rose 2 basis points to 1.55 per cent.\nTotal allowances for the quarter fell 67.9 per cent to $153 million, compared with $476 million a year ago.","news_type":1},"isVote":1,"tweetType":1,"viewCount":622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849716290,"gmtCreate":1635777201783,"gmtModify":1635777201905,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Mthly post. Waiting it&nbsp;to take off 🚀 to the next level😎","listText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Mthly post. Waiting it&nbsp;to take off 🚀 to the next level😎","text":"$AEM HOLDINGS LTD(AWX.SI)$Mthly post. Waiting it to take off 🚀 to the next level😎","images":[{"img":"https://static.tigerbbs.com/afd266c898bf375788296b0288cd17a8","width":"828","height":"1632"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849716290","isVote":1,"tweetType":1,"viewCount":456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":867867793,"gmtCreate":1633238742969,"gmtModify":1633238743117,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"Good news 👍🏼&nbsp;","listText":"Good news 👍🏼&nbsp;","text":"Good news 👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867867793","repostId":"2172968435","repostType":4,"repost":{"id":"2172968435","pubTimestamp":1633097043,"share":"https://www.laohu8.com/m/news/2172968435?lang=&edition=full","pubTime":"2021-10-01 22:04","market":"us","language":"en","title":"Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News","url":"https://stock-news.laohu8.com/highlight/detail?id=2172968435","media":"Investing.com","summary":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in pre","content":"<p>By Geoffrey Smith</p>\n<p>Investing.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.</p>\n<p>By (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.&nbsp; Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.</p>\n<p>Merck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.</p>\n<p>The study was stopped early, as is often the case when an experimental drug shows signs of efficacy.</p>\n<p>Scientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.</p>\n<p>Related Articles</p>\n<p>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</p>\n<p>Stocks under pressure as euro zone inflation hits 13-year high</p>\n<p>Merck's COVID-19 pill cuts risk of death, hospitalization by 50% in study</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-01 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","MRNA":"Moderna, Inc.","PFE":"辉瑞","NWS":"新闻集团"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2172968435","content_text":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.\nBy (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.  Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.\nMerck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.\nThe study was stopped early, as is often the case when an experimental drug shows signs of efficacy.\nScientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.\nRelated Articles\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\nStocks under pressure as euro zone inflation hits 13-year high\nMerck's COVID-19 pill cuts risk of death, hospitalization by 50% in study","news_type":1},"isVote":1,"tweetType":1,"viewCount":442,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867156183,"gmtCreate":1633229456797,"gmtModify":1633229456988,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"In watchlist&nbsp;","listText":"In watchlist&nbsp;","text":"In watchlist","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/867156183","repostId":"2172964534","repostType":4,"isVote":1,"tweetType":1,"viewCount":394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864195036,"gmtCreate":1633067922577,"gmtModify":1633073193154,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OV8.SI\">$SHENG SIONG GROUP LTD(OV8.SI)$</a>Be clam","listText":"<a href=\"https://laohu8.com/S/OV8.SI\">$SHENG SIONG GROUP LTD(OV8.SI)$</a>Be clam","text":"$SHENG SIONG GROUP LTD(OV8.SI)$Be clam","images":[{"img":"https://static.tigerbbs.com/b0a6b8003c8b094a66b949e662141808","width":"828","height":"1632"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864195036","isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":865805155,"gmtCreate":1632965085834,"gmtModify":1632965086012,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Mthly post.time to accumulate?","listText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Mthly post.time to accumulate?","text":"$AEM HOLDINGS LTD(AWX.SI)$Mthly post.time to accumulate?","images":[{"img":"https://static.tigerbbs.com/4914a93eb835c6be2e315278379d971e","width":"828","height":"1632"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865805155","isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"hots":[{"id":867156183,"gmtCreate":1633229456797,"gmtModify":1633229456988,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"In watchlist&nbsp;","listText":"In watchlist&nbsp;","text":"In watchlist","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/867156183","repostId":"2172964534","repostType":4,"repost":{"id":"2172964534","pubTimestamp":1633221732,"share":"https://www.laohu8.com/m/news/2172964534?lang=&edition=full","pubTime":"2021-10-03 08:42","market":"us","language":"en","title":"2 Leading Healthcare Stocks to Buy in 2021 and Beyond","url":"https://stock-news.laohu8.com/highlight/detail?id=2172964534","media":"Motley Fool","summary":"The future looks bright with these two supercharged stocks.","content":"<p>If you're looking for new stocks to add to your portfolio that can generate sustained growth and keep generating returns in all kinds of markets, <a href=\"https://laohu8.com/S/AONE.U\">one</a> excellent industry to look at is healthcare. While not all stocks in this sector perform the same in turbulent markets, many do provide products and services that customers need regardless of the economy -- and this can lend resilience to a long-term investor's portfolio.</p>\n<p>To that end, today, we're going to take a look at two high-growth companies in the healthcare space. One is a leader in medical robotics while the other helps healthcare companies run their businesses more efficiently. Let's get started.</p>\n<p><img src=\"https://static.tigerbbs.com/bc209e3e1fc5ad6f0407e698d4c85f5c\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h2>1. Intuitive Surgical</h2>\n<p>Medical robotics pioneer<b> Intuitive Surgical</b> (NASDAQ:ISRG) was founded in 1995 and has been a publicly traded entity for more than two decades. Since the IPO, its shares have skyrocketed more than 16,000%. In the past year alone, the stock is up more than 40%. With its shares now trading just shy of $1,000, it's no surprise that the company is planning to undergo a stock split in early October.</p>\n<p>The stock has soared for good reason. Intuitive dominates the global surgical robotics market (more than three-quarters of it, in fact), most notably with its da Vinci Surgical System. Its approach has become more and more widely accepted -- and so Intuitive's revenue over the past decade has grown nearly 150% while net income has risen about 114%.</p>\n<p>And the company is just getting started. The global surgical robotics industry is expected to grow exponentially in the years ahead as an increasing number of medical providers utilize these tools in minimally invasive procedures due to their efficiency, accuracy, and ability to generate more positive post-surgery outcomes, such as shorter inpatient care.</p>\n<p>An investment in Intuitive Surgical could generate sustained returns for many years as it expands its footprint in this multi-billion-dollar industry and as reliance on surgical robotics continues to grow.</p>\n<h2>2. Veeva Systems</h2>\n<p>Cloud solutions provider <b>Veeva Systems</b> (NYSE:VEEV) may not be a name that immediately comes to mind when thinking about the healthcare sector, but it's a compelling choice for long-term investors to consider. The company helps healthcare companies -- ranging from household-name pharmaceutical giants to smaller life sciences entities -- effectively store their information.</p>\n<p>Veeva clients seem to appreciate what they do. The company has a long and respectable history of growth, having increased revenue more than 160% and net income nearly 390% over the past five years.</p>\n<p>And the company remains on track. For the first half of its fiscal 2022 (ended Jul. 31), Veeva reported a revenue increase of about 29% from the year-ago period. This was driven by a 28% boost in its subscription services as well as a 33% increase in its professional and other services. Net income increased about 25% during the same time period.</p>\n<p>Veeva's stock isn't cheap, trading at around $285 a share and a price-to-sales (P/S) ratio of about 26. But it's also safe to say that these kinds of valuations are something investors have come to expect from stocks in the high-growth SaaS space. Shares of the company have consistently appreciated over the years -- and even at its current premium valuation, Wall Street thinks the stock has upside of as much as 40% over the next 12 months.</p>\n<p>Finally, demand for Veeva's products and services isn't likely going anywhere, and its list of customers -- including such big names as <b>Merck</b>, <b>Eli Lilly</b>, and <b>Bayer </b>-- is only growing. Veeva Systems is a stock for the long haul. And if you're not thrilled about its current price, there's no harm in dipping your toe by investing in fractional shares of this stock for now.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Leading Healthcare Stocks to Buy in 2021 and Beyond</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Leading Healthcare Stocks to Buy in 2021 and Beyond\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-03 08:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/02/2-leading-healthcare-stocks-buy-in-2021-and-beyond/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you're looking for new stocks to add to your portfolio that can generate sustained growth and keep generating returns in all kinds of markets, one excellent industry to look at is healthcare. While...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/02/2-leading-healthcare-stocks-buy-in-2021-and-beyond/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/10/02/2-leading-healthcare-stocks-buy-in-2021-and-beyond/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2172964534","content_text":"If you're looking for new stocks to add to your portfolio that can generate sustained growth and keep generating returns in all kinds of markets, one excellent industry to look at is healthcare. While not all stocks in this sector perform the same in turbulent markets, many do provide products and services that customers need regardless of the economy -- and this can lend resilience to a long-term investor's portfolio.\nTo that end, today, we're going to take a look at two high-growth companies in the healthcare space. One is a leader in medical robotics while the other helps healthcare companies run their businesses more efficiently. Let's get started.\n\nImage source: Getty Images.\n1. Intuitive Surgical\nMedical robotics pioneer Intuitive Surgical (NASDAQ:ISRG) was founded in 1995 and has been a publicly traded entity for more than two decades. Since the IPO, its shares have skyrocketed more than 16,000%. In the past year alone, the stock is up more than 40%. With its shares now trading just shy of $1,000, it's no surprise that the company is planning to undergo a stock split in early October.\nThe stock has soared for good reason. Intuitive dominates the global surgical robotics market (more than three-quarters of it, in fact), most notably with its da Vinci Surgical System. Its approach has become more and more widely accepted -- and so Intuitive's revenue over the past decade has grown nearly 150% while net income has risen about 114%.\nAnd the company is just getting started. The global surgical robotics industry is expected to grow exponentially in the years ahead as an increasing number of medical providers utilize these tools in minimally invasive procedures due to their efficiency, accuracy, and ability to generate more positive post-surgery outcomes, such as shorter inpatient care.\nAn investment in Intuitive Surgical could generate sustained returns for many years as it expands its footprint in this multi-billion-dollar industry and as reliance on surgical robotics continues to grow.\n2. Veeva Systems\nCloud solutions provider Veeva Systems (NYSE:VEEV) may not be a name that immediately comes to mind when thinking about the healthcare sector, but it's a compelling choice for long-term investors to consider. The company helps healthcare companies -- ranging from household-name pharmaceutical giants to smaller life sciences entities -- effectively store their information.\nVeeva clients seem to appreciate what they do. The company has a long and respectable history of growth, having increased revenue more than 160% and net income nearly 390% over the past five years.\nAnd the company remains on track. For the first half of its fiscal 2022 (ended Jul. 31), Veeva reported a revenue increase of about 29% from the year-ago period. This was driven by a 28% boost in its subscription services as well as a 33% increase in its professional and other services. Net income increased about 25% during the same time period.\nVeeva's stock isn't cheap, trading at around $285 a share and a price-to-sales (P/S) ratio of about 26. But it's also safe to say that these kinds of valuations are something investors have come to expect from stocks in the high-growth SaaS space. Shares of the company have consistently appreciated over the years -- and even at its current premium valuation, Wall Street thinks the stock has upside of as much as 40% over the next 12 months.\nFinally, demand for Veeva's products and services isn't likely going anywhere, and its list of customers -- including such big names as Merck, Eli Lilly, and Bayer -- is only growing. Veeva Systems is a stock for the long haul. And if you're not thrilled about its current price, there's no harm in dipping your toe by investing in fractional shares of this stock for now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600222582,"gmtCreate":1638161340954,"gmtModify":1638161341059,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600222582","repostId":"1119853738","repostType":2,"isVote":1,"tweetType":1,"viewCount":487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690236166,"gmtCreate":1639668541645,"gmtModify":1639668564381,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>👏🏻 Keep gg up!","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>👏🏻 Keep gg up!","text":"$Pfizer(PFE)$👏🏻 Keep gg up!","images":[{"img":"https://static.tigerbbs.com/93f1b8a0fa8decc2bbbbcfdff64c20fc","width":"750","height":"2214"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/690236166","isVote":1,"tweetType":1,"viewCount":368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":865805155,"gmtCreate":1632965085834,"gmtModify":1632965086012,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Mthly post.time to accumulate?","listText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Mthly post.time to accumulate?","text":"$AEM HOLDINGS LTD(AWX.SI)$Mthly post.time to accumulate?","images":[{"img":"https://static.tigerbbs.com/4914a93eb835c6be2e315278379d971e","width":"828","height":"1632"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865805155","isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":693319960,"gmtCreate":1639969831044,"gmtModify":1639969831174,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AIY.SI\">$IFAST CORPORATION LTD.(AIY.SI)$</a>$7.50? 🤔","listText":"<a href=\"https://laohu8.com/S/AIY.SI\">$IFAST CORPORATION LTD.(AIY.SI)$</a>$7.50? 🤔","text":"$IFAST CORPORATION LTD.(AIY.SI)$$7.50? 🤔","images":[{"img":"https://static.tigerbbs.com/54e5e42853b745936f11f12a89fba6b7","width":"750","height":"1687"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693319960","isVote":1,"tweetType":1,"viewCount":955,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841868505,"gmtCreate":1635901814533,"gmtModify":1635901814635,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841868505","repostId":"2180317907","repostType":4,"isVote":1,"tweetType":1,"viewCount":622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849716290,"gmtCreate":1635777201783,"gmtModify":1635777201905,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Mthly post. Waiting it&nbsp;to take off 🚀 to the next level😎","listText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Mthly post. Waiting it&nbsp;to take off 🚀 to the next level😎","text":"$AEM HOLDINGS LTD(AWX.SI)$Mthly post. Waiting it to take off 🚀 to the next level😎","images":[{"img":"https://static.tigerbbs.com/afd266c898bf375788296b0288cd17a8","width":"828","height":"1632"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849716290","isVote":1,"tweetType":1,"viewCount":456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":867867793,"gmtCreate":1633238742969,"gmtModify":1633238743117,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"Good news 👍🏼&nbsp;","listText":"Good news 👍🏼&nbsp;","text":"Good news 👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867867793","repostId":"2172968435","repostType":4,"repost":{"id":"2172968435","pubTimestamp":1633097043,"share":"https://www.laohu8.com/m/news/2172968435?lang=&edition=full","pubTime":"2021-10-01 22:04","market":"us","language":"en","title":"Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News","url":"https://stock-news.laohu8.com/highlight/detail?id=2172968435","media":"Investing.com","summary":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in pre","content":"<p>By Geoffrey Smith</p>\n<p>Investing.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.</p>\n<p>By (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.&nbsp; Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.</p>\n<p>Merck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.</p>\n<p>The study was stopped early, as is often the case when an experimental drug shows signs of efficacy.</p>\n<p>Scientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.</p>\n<p>Related Articles</p>\n<p>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</p>\n<p>Stocks under pressure as euro zone inflation hits 13-year high</p>\n<p>Merck's COVID-19 pill cuts risk of death, hospitalization by 50% in study</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-01 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","MRNA":"Moderna, Inc.","PFE":"辉瑞","NWS":"新闻集团"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2172968435","content_text":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.\nBy (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.  Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.\nMerck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.\nThe study was stopped early, as is often the case when an experimental drug shows signs of efficacy.\nScientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.\nRelated Articles\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\nStocks under pressure as euro zone inflation hits 13-year high\nMerck's COVID-19 pill cuts risk of death, hospitalization by 50% in study","news_type":1},"isVote":1,"tweetType":1,"viewCount":442,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864195036,"gmtCreate":1633067922577,"gmtModify":1633073193154,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OV8.SI\">$SHENG SIONG GROUP LTD(OV8.SI)$</a>Be clam","listText":"<a href=\"https://laohu8.com/S/OV8.SI\">$SHENG SIONG GROUP LTD(OV8.SI)$</a>Be clam","text":"$SHENG SIONG GROUP LTD(OV8.SI)$Be clam","images":[{"img":"https://static.tigerbbs.com/b0a6b8003c8b094a66b949e662141808","width":"828","height":"1632"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864195036","isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":879160532,"gmtCreate":1636691198526,"gmtModify":1636691198821,"author":{"id":"3569379973417395","authorId":"3569379973417395","name":"LEngLEng","avatar":"https://static.tigerbbs.com/0a6eb8d5f9130d054d135b849ead65ff","crmLevel":5,"crmLevelSwitch":0},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Wow…👍🏼&nbsp;Any good news for today bull run?","listText":"<a href=\"https://laohu8.com/S/AWX.SI\">$AEM HOLDINGS LTD(AWX.SI)$</a>Wow…👍🏼&nbsp;Any good news for today bull run?","text":"$AEM HOLDINGS LTD(AWX.SI)$Wow…👍🏼 Any good news for today bull run?","images":[{"img":"https://static.tigerbbs.com/40bd68542e08820e79726dd8a908399e","width":"750","height":"1460"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879160532","isVote":1,"tweetType":1,"viewCount":555,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}